Original Articles

Vancomycin Minimum Inhibitory Concentration Trend in Methicillin Resistant Staphylococcus aureus from a Tertiary Care Hospital in Central Kerala, India

Abstract

Background: Methicillin resistant Staphylococcus aureus (MRSA) is an important cause of nosocomial infections. Vancomycin is one of the mainstays for the cure of MRSA infections and vancomycin MIC creep have been reported from different parts of the world. This study evaluated the trends of vancomycin MIC among the MRSA and analysed its relationship with vancomycin consumption.
Methods: During the six years of this retrospective study, the MIC of Oxacillin and Vancomycin of all clinically relevant Staphylococcus aureus were retrieved from the automated Vitek-2 compact system. The consumption rate of vancomycin in our hospital as the defined daily doses (DDDs) per 1000 bed-days were collected from Pharmacy services. The data obtained were statistically analysed. 
Results: Out of 1,19,112 total samples processed 2.02% were found as Staphylococcus aureus among which 44.7% were MRSA. Over the study period, all the MRSA isolates were susceptible to vancomycin and there was a statistically significant increase in isolates with vancomycin MIC =1 µg/ml depicting the MIC creep phenomenon in our isolates. But a significant correlation between DDDs/1000 bed days of vancomycin and increase in MIC range could not be established.
Conclusion: There is a dire need to identify the trend of vancomycin MICs in our local area to assess the existence of creep trend and warn the clinicians of these disastrous strains. Sensitization about this type of MRSA MIC creep among the primary health physician is also needed to implement the control measures and limit its spread in communities.

1. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23(1):99-139.
2. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1(3):147-55.
3. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46(2):193-200.
4. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2024 http://www.whocc.no/atcddd/.
5. Murray CJ, Ikuta KS, Sharara F. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022; 399(10325):629-655.
6. Samia NI, Robicsek A, Heesterbeek H, et al. Methicillin-resistant Staphylococcus aureus nosocomial infection has a distinct epidemiological position and acts as a marker for overall hospital-acquired infection trends. Sci Rep 2022; 12(1):17007.
7. Hanberger H, Walther S, Leone M, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 2011; 38:331-5.
8. Álvarez A, Fernández L, Gutiérrez D, et al. Methicillin-resistant Staphylococcus aureus in hospitals: latest trends and treatments based on bacteriophages. J Clin Microbiol 2019; 57:e01006-19.
9. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1):1-45.
10. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350(9092):1670-3.
11. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med 2017; 90(2):269-81.
12. Niveditha N, Sujatha S. Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus Insights from a tertiary care center, South India. Braz J Infect Dis 2015; 19:585-9.
13. Chang W, Xiaoling M, Gao P, et al. Vancomycin MIC creep in methicillin resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian J Med Microbiol 2015; 33:262-6.
14. Chatterjee A, Rai S, Guddattu V, et al. Is methicillinresistant Staphylococcus aureus infection associated with higher mortality and morbidity in hospitalized patients? A cohort study of 551 patients from South Western India. Risk Manag Healthc Pol 2018; 11:243-50.
15. Abimannan N, Sumathi G, Krishnarajasekhar OR, et al. Clonal clusters and virulence factors of methicillin-resistant Staphylococcus aureus: evidence for community-acquired methicillin-resistant Staphylococcus aureus infiltration into hospital settings in Chennai, South India. Indian J Med Microbiol 2019; 37(3):326-36.
16. Mallick SK, Basak S. MRSA–Too many hurdles to overcome: A study from Central India. Trop Doct 2010; 40:108-10.
17. Tiemersma EW, Bronzwaer SL, Lyytikäinen O, et al. European antimicrobial resistance surveillance system participants. Methicillin resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10:1627-34.
18. Lohan K, Sangwan J, Mane P, et al. Prevalence pattern of MRSA from a rural medical college of North India: A cause of concern. J Family Med Prim Care 2021; 10:752-7
19. Sanjana RK, Shah R, Chaudhary N, et al. Prevalence and antimicrobial susceptibility pattern of Methicillin resistant Staphylococcus aureus (MRSA) in CMS teaching hospital: A preliminary report. J Coll Med Sci Nepal 2010; 6:1 6
20. Shrestha B, Pokhrel BM, Mohapatra TM. Antibiotic susceptibility pattern of nosocomial isolates of Staphylococcus aureus in a tertiary care Hospital, Nepal. J Nepal Med Assoc 2009; 48:175.
21. Tiwari HK, Sapkota D, Sen MR. High prevalence of multidrugresistant MRSA in a tertiary care hospital of northern india. Infect Drug Resist 2008; 1:57–61.
22. Dilnessa T, Bitew A. Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus isolated from clinical samples at yekatit 12 hospital medical college, addis ababa, ethiopia. BMC Infect Dis 2016; 16:398.
23. Olowe O, Eniola K, Olowe R, et al. Antimicrobial susceptibility and betalactamase detection of MRSA in osogbo, SW nigeria. Nature and Science 2007; 5:44-8.
24. Ketaki Vyankatesh Kulkarni D, Kulkarni D. Evaluation of vancomycin mic creep phenomenon in MRSA isolates from clinical samples. Int J Recent Sci Res 2020; 11(03):37797-800.
25. Steinkraus G, White R, Friedrich L. Vancomycin MIC Creep in non-vancomycin- intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60: 788-94.
26. Husain A, Rawat V, Umesh M, et al. Vancomycin, linezolid and daptomycin susceptibility pattern among clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) from Sub Himalyan Center. J Lab Physicians 2018; 10:145-8.
Files
IssueVol 13 No 1 (2025) QRcode
SectionOriginal Articles
DOI https://doi.org/10.18502/jmb.v13i1.18039
Keywords
MIC Creep MRSA Staphylococcus aureus Vancomycin.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
M A, Valsan C. Vancomycin Minimum Inhibitory Concentration Trend in Methicillin Resistant Staphylococcus aureus from a Tertiary Care Hospital in Central Kerala, India. J Med Bacteriol. 2025;13(1):1-8.